Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

April 7, 2020

Primary Completion Date

July 29, 2022

Study Completion Date

February 24, 2025

Conditions
Advanced CancerMetastatic CancerMalignant Neoplastic Disease
Interventions
DRUG

MRTX849

KRAS G12C Inhibitor

DRUG

TNO155

SHP2 Inhibitor

Trial Locations (17)

10016

Local Institution - 002-813, New York

10065

Local Institution - 002-806, New York

48377

Local Institution - 002-811, Novi

53226

Local Institution - 002-810, Milwaukee

60611

Local Institution - 002-828, Chicago

63110

Local Institution - 002-809 A, St Louis

63129

Local Institution - 002-809 C, St Louis

63130

Local Institution - 002-809, St Louis

63136

Local Institution - 002-809 E, St Louis

63141

Local Institution - 002-809 B, Creve Coeur

63376

Local Institution - 002-809 D, City of Saint Peters

67214

Local Institution - 002-942, Wichita

78229

Local Institution - 002-801, San Antonio

90095

Local Institution - 002-805, Los Angeles

92868

Local Institution - 002-803, Orange

02114

Local Institution - 002-804, Boston

02215

Local Institution - 002-808, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Mirati Therapeutics Inc.

INDUSTRY

NCT04330664 - Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) | Biotech Hunter | Biotech Hunter